搜尋
產品
社群
市場
新聞
經紀商
更多
TW
立即開始
Insulet Corporation
看多
2022年12月1日
Two healthcare leaders, which one is best to own?
1
取得這個圖表
取得這個圖表
PODD
&
DXCM
are leading the sectors recovery.
Both are in the Medical Products Industry for diabetes.
Insulent (PODD) normally outperforms DexCom (DXCM) during and after a correction. Then, when they are in sustained uptrends, DXCM outperforms.
For the recent correction, PODD has a -45% deep base while DXCM has a -58%.
PODD bottmed 4 weeks before DXCM, but DXCM has rallied +74% and PODD +65% since.
So, it really depends on your strategy. If you are looking for aplha then
DXCM
is the stock for you but, if you prefer low beta then
PODD
is better.
Remember that aplha plays in both ways!
Which are you trading?
I'll trade the first that makes a new high.
dpuleo19
關注
更多:
Chart Patterns
diabetes
DXCM
healthcare
Technical Indicators
PODD
Trend Analysis
dpuleo19
關注
更多:
免責聲明
這些資訊和出版物並不意味著也不構成TradingView提供或認可的金融、投資、交易或其他類型的意見或建議。請在
使用條款
閱讀更多資訊。